Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903
NCT ID: NCT05155072
Last Updated: 2021-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
31 participants
INTERVENTIONAL
2020-05-15
2020-09-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
NCT06151210
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
NCT04784910
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers
NCT02757144
A Study to Evaluate the Efficacy and Safety of DA-5204
NCT02282670
A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
NCT07139886
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Sequence B
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Sequence C
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Sequence D
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Sequence E
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Sequence F
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DW1903
DW1903
DW1903-R1
DW1903-R1
DW1903-R2
DW1903-R2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18 and 30 kg/m2
* Body weight ≥50kg
Exclusion Criteria
19 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungbuk National University Hospital
Cheongju-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW1903-101D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.